Primecap Management Co. CA Has $77.24 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Primecap Management Co. CA raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 325,956 shares of the medical research company’s stock after buying an additional 780 shares during the quarter. Primecap Management Co. CA owned 0.18% of IQVIA worth $77,242,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in IQVIA during the 3rd quarter worth $28,000. Versant Capital Management Inc raised its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA during the 2nd quarter valued at $27,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA during the 2nd quarter worth $29,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on IQV shares. Barclays cut their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Evercore ISI reduced their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. BTIG Research decreased their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. TD Cowen reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Up 1.6 %

NYSE:IQV opened at $197.57 on Friday. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market cap of $35.86 billion, a PE ratio of 25.93, a P/E/G ratio of 1.97 and a beta of 1.51. The firm’s 50 day simple moving average is $223.40 and its 200 day simple moving average is $227.35.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.